Worldwide access to Paxlovid remains inequitable

In a Think Global Health article, IHME staff examine the barriers to acquiring the antiviral Paxlovid, which can greatly reduce the chance of COVID-19 hospitalizations and deaths.

• Low- and middle-income nations must contend with licensing dilemmas, lack of supplies, and high costs to gain access to Paxlovid.

• “This would be similar to the vaccine situation when rich countries started giving three or four doses while other countries had no vaccines,” said professor Ali Mokdad.

• IHME estimates that 82% of people who died from COVID-19 did not live in high-income countries. The authors call on high-income countries to swiftly make Paxlovid available to people everywhere before a new, more severe variant arises.

https://mailchi.mp/healthdata/thousands-of-lives-could-be-saved-by-paxlovid

Créditos: Comité científico Covid